7–13 September 2026
What moved in longevity science this week, what it changes for what you take, move, eat and measure, and what is being sold far ahead of its evidence. Global signal, India lens.
THE SHORT VERSION
Nothing this week changes what you should do. You may have seen that an AI-designed drug made patients biologically younger: that analysis covered 42 patients over 12 weeks with no comparison group, so it cannot tell you the drug did anything. Vitamin D after a heart attack now has 4.2 years of outcome data and did not clearly cut heart events (H4)1. If you take it for bone health or a measured deficiency, this does not apply. Nothing here justifies buying a biological age test.
TAKE
Vitamin D after a heart attack did not clearly reduce heart events
TARGET-D reported its 4.2-year result, and it did not show a clear reduction in cardiovascular events.
Targeted vitamin D management did not clearly reduce major cardiovascular events after myocardial infarction, over 4.2 years of follow-up (H4)1.
It says nothing about vitamin D for bone health, or for a measured deficiency without a heart attack.
Two company cardiovascular programmes also stopped short of an outcome. One missed its endpoint in a randomised outcomes trial, company-reported and unpublished (H4)2. The other, an anti-inflammatory drug's two randomized trials, was discontinued for reasons not stated 3.
Harms: no adverse-event data appear in the available reporting for any of the three.
DOES THIS CHANGE WHAT I SHOULD DO?
NO. TARGET-D did not find a clear reduction in major cardiovascular events over 4.2 years (H4)1. A null trial does not prove no effect, but nothing here supports taking vitamin D for the heart.
Six clocks fell in a single-arm trial of an AI-designed drug
Insilico published blood-sample analysis from its completed Phase IIa of rentosertib in idiopathic pulmonary fibrosis.
Predicted biological age fell across six proteomic clocks over 12 weeks in 42 patients (H2)4.
The trial was single-arm. With no control group, the fall cannot be attributed to the drug.
No new efficacy data on the drug itself appeared. Several outlets dropped this from their coverage 56.
Harms: safety and tolerability were not what this analysis measured 4.
DOES THIS CHANGE WHAT I SHOULD DO?
NO. This is a fibrosis drug reported on an aging endpoint it was never tested against. It tells no one, fibrosis patient or otherwise, that they will age more slowly.
Folate and homocysteine tracked biological aging in Indian older adults
An Indian cohort measured nutrient status against aging clocks over 4.5 years 7.
In adults aged 60 and over, higher folate was associated with slower biological aging and higher homocysteine with faster aging, on Phenotypic Age and methylation-based clocks (H1)7.
This is association within a cohort. No supplement was given, so no benefit or harm from taking folate or B12 is established.
IndiaThe data come from LASI-DAD, a study built for Indian dementia research, so the population is the right one for Indian screening debates about folate and homocysteine 7. The study measured folate and homocysteine, not B12, and an association cannot tell you whether screening or treating helps.
DOES THIS CHANGE WHAT I SHOULD DO?
NO. Low B12 or folate on a blood test is a clinical matter with its own treatment, and that has not changed. A supplementation trial against an aging endpoint would be the thing to watch; none is in the record.
MEASURE
Clocks moved this week for cash, saunas and exercise
Three results show how easily an epigenetic age reading shifts. Two more show how little the reading carries.
A randomized trial gave low-income US mothers $333 or $20 a month for four years. Children in the high-cash group showed a small reduction in DunedinPACE aging (H3)8.
Eighteen firefighters using a portable sauna showed higher DNAmVO2max and AdaptAge, and higher DamAge as well (H2)9.
Six months of exercise lowered epigenetic age in proportion to volume, plateauing near WHO guideline levels (H2)10.
Proteomic clock age acceleration tracked disease and mortality risk, but added limited predictive value beyond standard lifestyle risk indicators (H1)11.
Genflow's beagle trial 1213 used a methylation clock as primary endpoint, the same week clock-to-outcome value was reported as limited (P2)1114.
Harms: none of these clock studies reports adverse-event data. The risk is what someone does with the number.
One study compared T-cell p16INK4a against five methylation clocks in 251 women treated for early breast cancer (H1)15. Whether the methods ranked the same women differently is not reported in the available coverage. The demonstrated discordance is elsewhere: 1,752 Alzheimer's polygenic score configurations placed the same individuals in both top and bottom risk strata (M0)16.
DOES THIS CHANGE WHAT I SHOULD DO?
NO. Treat any clock reading you pay for as one configuration among many, taken at one moment. Clock age acceleration tracks disease and mortality risk, but adds little beyond standard risk factors a doctor already measures (H1)11, and no study shows moving the number changes the outcome. Even the most useful result, exercise, only moved a clock: the curve flattened near activity guideline levels 10.
WHAT STILL HOLDS
Standing positions this week. Nothing moved them.
No clock reading has been shown to predict how long or how well you live better than ordinary risk factors already do.
Proteomic clock age acceleration tracked disease and mortality risk, but added limited predictive value beyond standard lifestyle risk indicators (H1)11. What would change this is a clock that improves on standard indicators, or an intervention that moves a clock and an outcome together.
Animal lifespan results are still not human results.
One arrived this week: midlife suppression of growth hormone receptor production extended lifespan in mice (P2)17. A second mouse study reduced colitis severity with systemic senolytics (P2)18, which is a disease model, not a lifespan result.
A trial can meet its primary endpoint without anyone living longer or better.
Genflow's beagle trial used a methylation clock as that endpoint (P2)14.
WHAT DIDN'T MOVE
GLP-1 drugs and lifespan.
Mouse coverage continued, and a 75-adult pilot randomizing GLP-1 patients to standard care, protein, or protein plus spices was registered 19. No human outcome data on GLP-1 for aging appeared.
Muscle and bone during weight loss.
A review sets out how weight loss raises bone turnover and lowers bone density, a drug-driven counterweight still without outcome data 20.
Senolytics.
A Phase II of dasatinib plus quercetin in 80 frail or prefrail adults with HIV, aged 50+, was registered 21; systemic senolytics also reduced colitis severity in mice (P2)18. Registrations are plans.
NAD+ precursors.
NAD+ dysregulation was implicated in mouse colitis via T-cell senescence (P2)18. Human trials still measure metabolites, not outcomes.
Metformin and rapamycin.
No new trial data for either.
Population-level interpretation of published evidence. Not medical advice, and not a recommendation to start or stop any prescription.
Sources
Scientist working at the intersection of computation, biology and medicine. Longevity, Interpreted. exists to understand the evidence, not sell an intervention.
All issues · Subscribe · suchee.org · LinkedIn · Scholar